Insilico Medicine, a Hong Kong AI-based drug discovery company, closed a $37 million Series B funding round led by Qiming Venture Partners with other China investors participating. Last week Insilico published an article in Nature Biotechnology that detailed the company’s search for novel molecules that target the discoidin domain receptor 1 (DDR1) pathway. The entire process moved from thousands of potential candidates to a final compound tested in mice in just 21 days. Insilico says the Series B will be used to commercialize its generative chemistry and target identification technology.
Source: China Biotoday